Organizing pneumonia after rituximab therapy: Two cases

Abstract Rituximab, a chimeric monoclonal antibody against CD20, very rarely causes lung toxicity. Clinical presentations include lung infiltrates, alveolar hemorrhage, and adult respiratory distress syndrome. Three cases of organizing pneumoinia (formerly called bronchiolitis obliterans with organi...

Full description

Saved in:
Bibliographic Details
Published in:Joint, bone, spine : revue du rhumatisme bone, spine : revue du rhumatisme, 2008-05, Vol.75 (3), p.362-365
Main Authors: Soubrier, Martin, Jeannin, Gaëlle, Kemeny, Jean Louis, Tournadre, Anne, Caillot, Nicolas, Caillaud, Denis, Dubost, Jean Jacques
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal - adverse effects
Antibodies, Monoclonal, Murine-Derived
Antirheumatic Agents - adverse effects
Arthritis, Rheumatoid - drug therapy
BOOP
Castleman's disease
Female
Humans
Internal Medicine
Middle Aged
Organizing pneumonia
Pneumonia - chemically induced
Pneumonia - drug therapy
Rheumatoid arthritis
Rheumatology
Rituximab
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Rituximab, a chimeric monoclonal antibody against CD20, very rarely causes lung toxicity. Clinical presentations include lung infiltrates, alveolar hemorrhage, and adult respiratory distress syndrome. Three cases of organizing pneumoinia (formerly called bronchiolitis obliterans with organizing pneumonia or BOOP) have been reported. In our experience, organizing pneumonia occurred in 2 of 25 patients treated with rituximab, for RA and Castleman's disease, respectively. Because organizing pneumonia may be asymptomatic, as illustrated by one of our cases, we recommend obtaining a chest radiograph routinely before rituximab re-treatment.
ISSN:1297-319X
1778-7254
DOI:10.1016/j.jbspin.2007.10.009